NOVO B NOVO NORDISK A/S

Trading in Novo Nordisk shares by board members, executives and associated persons

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Novo Holdings A/S, associated to Kasim Kutay

2

Reason for the notification

a)

Position/status

Member of the Board of Directors

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer

a)

Name

Novo Nordisk A&S

b)

LEI

549300DAQ1CVT6CXN342

4

Details of the transaction(s)

a)

Description of the financial instrument, type of instrument,

Identification code

Shares

Novo Nordisk B DK0062498333

b)

Nature of the transaction

Sale of shares

c)

Price(s) and volume(s)

  
Price(s)Volume(s)
DKK 860.026,311,250 shares
  

d)

Aggregated information

  • Aggregated volume
  • Price



6,311,250 shares

DKK 5,427,801,225.00

e)

Date of the transaction

2024-05-06

f)

Place of the transaction

Outside a trading venue

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit , , , , and .

Contacts for further information

Media: 
Ambre James-Brown







Liz Skrbkova (US)







Investors: 
Daniel Muusmann Bohsen







Jacob Martin Wiborg Rode







David Heiberg Landsted







Mark Joseph Root (US)







Sina Meyer





Frederik Taylor Pitter





Ida Melvold Gjøsund





 

Company announcement No 39 / 2024

Attachment



EN
06/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NOVO NORDISK A/S

 PRESS RELEASE

Novo Nordisk to streamline operations and reinvest for growth

Novo Nordisk to streamline operations and reinvest for growth Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patientsIntention to reduce ~9,000 roles globally with the expectation to deliver DKK 8bn of annualised savings by the end of 2026One-off restructuring costs of DKK 8bn leading to an updated full-year 2025 operating profit growth outlook of 4–10% at CER Bagsværd, Denmark, 10 September 2025 – Novo Nordisk today announced a company-wide transformation to simplify its organisation, im...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch